About
Bavarian Nordic (PINK:BVNRY) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 16 2026
Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine
Mar 27 2026
Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years
Mar 12 2026
Bavarian Nordic Launches Next Tranche of Share Buy-Back Program
Mar 12 2026
Bavarian Nordic Publishes Annual Report 2025
Mar 11 2026
Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement
Financials
Revenue
$6.24 B
Market Cap
$2.33 B
P/E Ratio
10.93
EPS
0.91
Translate